Strides Pharma Science is currently trading at Rs. 457.30, up by 12.20 points or 2.74% from its previous closing of Rs. 445.10 on the BSE.
The scrip opened at Rs. 452.00 and has touched a high and low of Rs. 468.00 and Rs. 449.15 respectively. So far 213452 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 737.02 on 04-Apr-2018 and a 52 week low of Rs. 334.10 on 08-Jun-2018.
Last one week high and low of the scrip stood at Rs. 468.00 and Rs. 434.70 respectively. The current market cap of the company is Rs. 4102.71 crore.
The promoters holding in the company stood at 30.79%, while Institutions and Non-Institutions held 47.61% and 21.60% respectively.
Strides Pharma Science (Strides) has received the United States Food & Drug Administration (USFDA) approval for its greenfield oral dosage facility in Singapore. With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a Manufacturing and Research and Development footprint in Singapore.
The facility will complement Strides’ existing manufacturing base and will help meet increased demand from its fast?growing regulated markets business across US, Australia, UK and Europe. The facility operating at its peak capacity will produce around 1.4 billion tablets and hard gelatin capsules.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |